Relmada Therapeutics Announced That The Pre-planned Interim Analysis Of Reliance II Phase 3 Study Indicated That The Study Is Futile And Is Unlikely To Meet The Primary Efficacy Endpoint With Statistical Significance
Relmada Therapeutics Announced That The Pre-planned Interim Analysis Of Reliance II Phase 3 Study Indicated That The Study Is Futile And Is Unlikely To Meet The Primary Efficacy Endpoint With Statistical Significance
Relmada therapeutics宣佈，預先計劃的Reliance II 3期研究的中期分析表明，該研究無效，並且不太可能以統計學顯著性達到主要療效終點。
- Reliance II is designed to evaluate REL-1017 as an adjunctive treatment for major depressive disorder (MDD), to be used in combination with other approved anti-depressants. No new safety signals were reported.
- The Data Monitoring Committee did not identify any new safety concerns
- Relmada to evaluate potential next steps for the REL-1017 program
- Relmada to continue to focus on the development of REL-P11 for metabolic disease
- Relmada is well capitalized with approximately $54.1 million in cash and cash equivalents as of September 30, 2024
- Reliance II旨在評估REL-1017作爲重度抑鬱症（MDD）的輔助治療，與其他批准的抗抑鬱藥物結合使用。沒有報告新的安全信號。
- 數據監測委員會沒有發現任何新的安全問題
- Relmada將評估REL-1017項目的潛在下一步
- Relmada將繼續專注於REL-P11在代謝疾病方面的發展
- 截至2024年9月30日，Relmada擁有約5410萬的現金及現金等價物，資本充足
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間